TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02664012

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Own Brand Menthol Cigarette
Description: combustible menthol cigarette brand style smoked most frequently by subject

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Menthol Cigarette #1
Description: VUSE® Digital Vapor Cigarette (menthol flavor, 14 mg nicotine)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Menthol Cigarette #2
Description: VUSE® Digital Vapor Cigarette (menthol flavor, 29 mg nicotine)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Menthol Cigarette #3
Description: VUSE® Digital Vapor Cigarette (menthol flavor, 36 mg nicotine)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leading U.S. Nicotine Gum
Description: 4 mg nicotine polacrilex gum
Study: NCT01342575

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-operative exposure maneuvers
Description: * Feet compression maneuver: Taking feet from the ankles, gentle pressure will be applied toward the cranium and maintained for 1 minute. X-rays and IONM will be performed~* Arm traction maneuver: Holding two strips around the wrists and using a dynamometer adjusted to 8 kg per side, sustained traction will be maintained for 1 minute. X-rays and IONM will be performed.~* Shoulder taping maneuver: Both shoulders will be pulled caudally with adhesive tape adjusted for a tension of 8 kg on each side. X-rays and IONM will be performed~* Arm traction plus feet compression maneuvers: Simultaneous combination of both maneuvers as described before. X-rays and IONM will be performed~* Shoulder taping plus feet compression maneuvers: Simultaneous combination of both maneuvers as described before. X-rays and IONM will be performed
Study: NCT04612283

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NGA-01 gel
Description: NGA-01 is a gel formulation with mostly herbal active ingredients

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A Placebo with no active ingredients
Study: NCT02368132

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Delivered TEP
Description: All TEP modules will be in a group format. Each call will take 1.5-2 hours. Each group will be comprised of 5-8 CGs who will call into a teleconference line at a pre-specified time. Groups will include spouse/partner-only or adult child-only CGs. The content of the calls will mirror those in the individual TEP delivered program. In addition to the group calls, they will receive individual care management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Delivered TEP
Description: Two mandatory modules that cover the stages of dementia and provide a brief introduction to problem solving techniques, action plan development, and coping skills, plus a menu of additional modules covering various content areas evaluated during the course of the monthly assessments (e.g., communication skills, behavioral management techniques, stress management and coping skills, longterm planning, etc.). Each individual TEP session will begin with reviewing education related to the selected module. The remainder of each session will involve coaching the caregiver on emotion-focused and problem focused coping strategies. The care manager will also discuss problem solving with the CG to reinforce the action plan and the educational component of the intervention.
Study: NCT00500578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Arm 1 = 6 Grams Over 18 hours Every 24 Hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Arm 2 = 2 Grams Over 3 Hours Every 8 Hours.
Study: NCT04635930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taping plus Traditional exercises
Description: The children will be taped 6 days per week for a total a period of 08 weeks. The tape will be used and keep the scapula in position for 3 days and the region will then be left to rest for 24 hours. Kinesio Taping will then be re-applied by the same experienced research assistants for another 3 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Taping plus Traditional exercises
Description: The children will be taped 6 days per week for a total a period of 08 weeks. The tape will be used and keep the scapula in position for 3 days and the region will then be left to rest for 24 hours. Kinesio Taping will then be re-applied by the same experienced research assistants for another 3 days.
Study: NCT02404870

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Canagliflozin is a new oral drug for the treatment of type 2 diabetes mellitus (T2DM), and is one of two recently FDA approved sodium glucose co-transporter 2 (SGLT2) inhibitors, which target renal glucose reabsorption and offer promising improvement in HbA1C.
Study: NCT04317807

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam Pill
Description: Levetiracetam is an anticonvulsant that is frequently used to treat epilepsy in children and adults due to its superior tolerability, ease of use and excellent safety profile. It is rapidly absorbed and rapidly crosses the blood-brain barrier. Levetiracetam does not affect metabolism of antipsychotic drugs and may normalize hippocampal hyperactivity by decreasing excessive glutamatergic and dopaminergic transmission, thereby making it an ideal agent to test the hypothesis that reducing excessive hippocampal activity may enhance treatment of early psychosis and prevent antipsychotic toxicity. Levetiracetam will be administered in 500 mg capsules twice a day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo pill (sugar pill) will look just like the levetiracetam pill but does not contain levetiracetam. Placebo will be taken along with optimal antipsychotic medication selected by either the outpatient provider or the hospital staff responsible for the participant's care. Participants will be instructed to take the placebo pill twice daily for 12 weeks.
Study: NCT05447845

Intervention type: DIAGNOSTIC_TEST
Intervention: Computerized visual acuity assessment program
Description: Each subject underwent visual acuity assessments using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart and the computerized program

Intervention type: DIAGNOSTIC_TEST
Intervention: Computerized visual acuity assessment program
Description: Each subject underwent visual acuity assessments using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart and the computerized program
Study: NCT01756365

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical transplantation of ACCE
Description: The culture of corneal epithelium strives to produce a reconstructed tissue with the therapeutical aim of treatment of limbal stem cell deficiency.
Study: NCT02479659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV testing commodity reinforcement
Description: HIV testing commodities were replenished directly (outside of the government supply) in the event of a stock-out by study staff. Treatment facilities were visited monthly to assess stock levels, and facility staff could contact study staff when stock levels were low.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV testing commodity reinforcement
Description: HIV testing commodities were replenished directly (outside of the government supply) in the event of a stock-out by study staff. Treatment facilities were visited monthly to assess stock levels, and facility staff could contact study staff when stock levels were low.
Study: NCT04584476

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: superior capsular reconstuction
Description: these patients underwent arthroscopic superior capsular reconstuction

Intervention type: PROCEDURE
Group type: OTHER
Intervention: partial rotator cuff repair
Description: these patients underwent arthroscopic partial rotator cuff repair
Study: NCT02479659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Policy reinforcement meeting
Description: District health officials met with facility staff to remind them of the current HIV testing policies for mothers and newborns in Zambia. Current policy states mothers with unknown or previously negative status should be tested every 3 months until the infant is 18 months of age. HIV-exposed newborns should be tested at 6 weeks and 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Policy reinforcement meeting
Description: District health officials met with facility staff to remind them of the current HIV testing policies for mothers and newborns in Zambia. Current policy states mothers with unknown or previously negative status should be tested every 3 months until the infant is 18 months of age. HIV-exposed newborns should be tested at 6 weeks and 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opt-out HIV testing for mothers and newborns
Description: Facility staff were instructed to examine the maternal HIV status on the under-five (U-5) or antenatal care (ANC) card for all infants attending their first U-5 visit and do the following:~* If marked Confirmed Exposed (CE), the health care worker conducted the DBS test on the infant only.~* If marked, Mother Status Unknown (MSU) or Confirmed Not Exposed (CNE) the mother or caregiver was asked if the mother had ever tested HIV-positive. If yes, a DBS was done on the infant only. If no, the mother was offered an HIV antibody test in an opt-out manner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Operational support for service integration
Description: The evaluation team worked with facility staff to identify efficient allocations of staff and tailor the order of services. A key component of the operational optimization was a new patient triaging approach that sorted patient U-5 cards into bins and used separate queues for three types of patients: 1) first visit infants (six weeks), 2) second visit or later infants who required immunizations and 3) infants who were scheduled to only receive growth monitoring.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community sensitization
Description: Health facility staff were instructed to communicate all aspects of the Comprehensive Intervention during ANC appointments, in-facility child birth deliveries, and postnatal care (PNC) visits. Additionally, at six week immunization visits, mothers and caregivers received group counseling on opt-out HIV screening service and the importance of regular HIV screening for mother and child health. Finally, the research team engaged Safe Motherhood Action Groups (SMAGs), community health workers (CHWs), and active neighborhood health committee members to further increase awareness in facility catchment areas. These community members completed low-touch community sensitization over changes that would be made to U-5 services.
Study: NCT03816553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg (3mg/kg for underweight patients).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib will be administered 250mg orally, once daily until progression.
Study: NCT01081782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4641
Description: 0.15 mg once per day for 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4641
Description: 0.1 mg once per day for 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4641
Description: 0.05 mg once per day for 26 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-4641 placebo
Description: Placebo once per day for 26 weeks
Study: NCT04010461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Intermittent theta burst stimulation TMS applied to the cortex to excite cerebral cortex

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Intermittent theta burst stimulation TMS applied to the cortex to excite cerebral cortex

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Intermittent theta burst stimulation TMS applied to the cortex to excite cerebral cortex

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: n-back working memory task
Description: Subjects perform an executive function task, in which they view the serial presentation of letters and decide whether or not a letter matches a letter presented 'n' letters back (2 letters or 1 letter)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: n-back working memory task
Description: Subjects perform an executive function task, in which they view the serial presentation of letters and decide whether or not a letter matches a letter presented 'n' letters back (2 letters or 1 letter)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: n-back working memory task
Description: Subjects perform an executive function task, in which they view the serial presentation of letters and decide whether or not a letter matches a letter presented 'n' letters back (2 letters or 1 letter)
Study: NCT03410992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Bimekizumab will be provided at pre-specified time intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Bimekizumab will be provided at pre-specified time intervals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
Study: NCT03044847

Intervention type: OTHER
Intervention: COPD group
Description: The treatments will be determined by their treating physicians and no additional investigational drugs will be applied to the patients included in this study.
Study: NCT01042834

Intervention type: OTHER
Intervention: Air pollution study on healthy volunteers.
Description: The subjects are examined three times:~* First the volunteers get used to equipments.~* Second and third the volunteers sleep in a pollution or purified air.
Study: NCT02912221

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incentive
Description: Both groups will receive fitbits to track their physical activity, however one arm of the study may receive additional incentives to achieve their step count goal.
Study: NCT02937181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline
Description: IV Ceftaroline will be given for 72 hours
Study: NCT03021317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTHar
Description: The patients will be given 80 Units subcutaneously of ACTHAR at the time of MS relapse daily for 10 days.
Study: NCT04378569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARQ-252 cream 0.3%
Description: ARQ-252 cream 0.3%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARQ-252 cream 0.3%
Description: ARQ-252 cream 0.3%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARQ-252 cream 0.1%
Description: ARQ-252 cream 0.1%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARQ-252 Vehicle Cream
Description: ARQ-252 Vehicle Cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARQ-252 Vehicle Cream
Description: ARQ-252 Vehicle Cream
Study: NCT04052880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab 1800 mg will be delivered by subcutaneous injection given through a syringe and needle by a manual push over approximately 3 to 5 minutes. Doses will be administered at alternating locations on the abdomen. Daratumumab will be administered weekly during treatment in Cycles 1 to 2, every 2 weeks during cycles 3-6, and every 4 weeks thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Subjects will receive 1.3 mg/m2 bortezomib as a subcutaneous infusion on Days 1, 8, and 15 during the 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: In Cycles 1 through 12, lenalidomide will be self-administered at a dose of 15 mg orally each day on Days 1 through 21 of each 28-day cycle.~For subjects with CrCl 30-60mL/min, lenalidomide will be reduced to 10mg daily, and for subjects with CrCl 15-30 mL/min, lenalidomide will be reduced to 5mg daily.~In maintenance phase: lenalidomide will be administered at one dose level below Cycles 1-12 dosing ie 10 mg orally daily.~In maintenance, for subjects with CrCl 30-60 mL/min, lenalidomide will be reduced to 5 mg daily during maintenance treatment, and for subjects with CrCl 15-30 mL/min, lenalidomide will be reduced to 5 mg every other day during maintenance treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be self-administered orally at a total dose of 20 mg weekly during cycles.~However, the dexamethasone 20 mg oral or IV (only if oral is not available) dose administered as a preinfusion medication on daratumumab infusion days replaces the oral dexamethasone dose for that day. Dexamethasone will be administered until the subject experiences disease progression or unacceptable toxicity.~In the maintenance phase, dexamethasone/steroid premedications may be tapered or discontinued in the absence of daratumumab related infusion reactions/based on patient tolerance. In the event of persistent daratumumab related infusion reactions, the least amount of steroid premedications needed to prevent the same may be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: During maintenance treatment, if choice of maintenance therapy includes ixazomib, ixazomib will be administered at 3 mg orally daily on Days 1,8, and 15 of each cycle. For subjects with CrCl 15-30 mL/min, ixazomib will be reduced to 2.3 mg once per week during maintenance treatment.
Study: NCT04307862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZEP-3Na 0.1%
Description: The Investigational Product will be applied topically twice daily for up to 4 weeks in the double blind phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZEP-3Na 1%
Description: The Investigational Product will be applied topically twice daily for up to 4 weeks in the double blind phase, with optional 2 weeks of open label with ZEP-3Na 1%.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle only
Description: he Investigational Product will be applied topically twice daily for up to 4 weeks in the double blind phase
Study: NCT05876429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New Standardized Accept Note
Description: A standardized accept note for transfer patients will be implemented, after stakeholder engagement and subsequent finalization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Existing Transfer Patient Admission Process
Description: Maintain existing transfer patient admission processes, across GMS, Cardiology, and Oncology services.
Study: NCT02121171

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ologen Collagen Matrix
Description: Use of ologen Collagen Matrix in trabeculectomy (ologen) Place ologen CM on the top of the loosely-sutured scleral flap under conjunctiva before suturing. It is recommended to suture the scleral flap with 1 or 2 stiches loosely and to coordinate with the tamponading effect of ologen CM to create a fluctuating scleral flap that prevents bleb wound adhesion and modulates aqueous humor outflow for ideal IOP control without leakage.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined trabeculotomy-trabeculectomy
Description: Combined trabeculotomy and trabeculectomy is a standard surgery for congenital glaucoma, however, it has its known complications.
Study: NCT03235037

Intervention type: DRUG
Group type: OTHER
Intervention: Levodopa
Description: The target dose of Sinemet is 2-10 mg per kilogram per day of levodopa. The initial dose will be determined by your weight and age and will start at a low dosage level, 1 mg per kilogram per day. The dose will be re-evaluated after the first 2 weeks and may be adjusted at each visit depending on your response to the drug.
Study: NCT01243060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almorexant
Description: 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almorexant
Description: 200mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem 10mg
Description: 10mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One-time dose of Placebo
Study: NCT00715234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminder/recall notices for vaccines
Description: 1. Receive a generic letter reminding them to make an appointment to get vaccines.~2. Receive a computer-generated telephone message at 1 week post initial letter.~3. Receive a computer-generated telephone message at 2 months post initial letter.~4. Receive a letter at 3 months post initial letter.
Study: NCT01061541

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix™-HepB low thio /
Description: One dose as intramuscular injection at 6, 10 and 14 weeks of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib 2.5
Description: One dose as intramuscular injection at 6, 10 and 14 weeks of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix™-HepB
Description: One dose as intramuscular injection at 6, 10 and 14 weeks of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hiberix™
Description: One dose as intramuscular injection at 6, 10 and 14 weeks of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Unconjugated Hib vaccine (plain PRP)
Description: One dose as intramuscular injection at 10 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Unconjugated Hib vaccine (plain PRP)
Description: One dose as intramuscular injection at 10 months of age
Study: NCT01151345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TILACEM
Description: At 08:00 hours on day 1, CIF-BIOTEC personnel will start to administer the study drug. Each volunteer will receive a single dose of 60 mg of Diltiazem. The study drugs will be ingested with 250 mL of drinking water. Research Pharmacy personnel will inspect the volunteer's oropharynx to ensure that he/she has swallowed the tablet and record their observations in the corresponding forms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANGIOTROFIN
Description: At 08:00 hours on day 1, CIF-BIOTEC Pharmacy personnel will start to administer the study drug. Each volunteer will receive a single dose of 60 mg of Diltiazem. The study drugs will be ingested with 250 mL of drinking water. Research Pharmacy personnel will inspect the volunteer's oropharynx to ensure that he/she has swallowed the tablet and record their observations in the corresponding forms.
Study: NCT01985100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen chamber